Sevinc, A. Et Al. 2018. Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia. ONCOTARGETS AND THERAPY , vol.11 , 419-426.

Sevinc, A., ÖZKAN, M., ÖZET, A., Dane, F., Oksuzoglu, B., Isikdogan, A., ... ÖZDEMİR, F.(2018). Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia. ONCOTARGETS AND THERAPY , vol.11, 419-426.

Sevinc, Alper Et Al. "Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia," ONCOTARGETS AND THERAPY , vol.11, 419-426, 2018

Sevinc, Alper Et Al. "Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia." ONCOTARGETS AND THERAPY , vol.11, pp.419-426, 2018

Sevinc, A. Et Al. (2018) . "Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia." ONCOTARGETS AND THERAPY , vol.11, pp.419-426.

@article{article, author={Alper Sevinc Et Al. }, title={Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia}, journal={ONCOTARGETS AND THERAPY}, year=2018, pages={419-426} }